Bisphosphonate therapy for skeletal metastases;Bisphosphonattherapie in der therapie von skelettmetastasen

Orthopade

Volumn 27, Issue 4, 1998, Pages 231-239

  Grauer, A ^a,b   Ziegler, R ^a  

^a Abt Inn Med I Endokrinol/S   (Germany)

^b Abteilung Innere Medizin   (Germany)

Author keywords

Bisphosphonates; Bone metastases; Hypercalcemia of malignancy

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID;

ARTICLE; BONE METASTASIS; BONE PAIN; BREAST CANCER; DRUG EFFECT; HIGH RISK POPULATION; HUMAN; HYPERCALCEMIA; OSTEOCLAST; OSTEOLYSIS; PAGET BONE DISEASE; PROPHYLAXIS;

BONE NEOPLASMS; BONE RESORPTION; CALCIUM; DIPHOSPHONATES; HUMANS; HYPERCALCEMIA;

EID: 0031970870     PISSN: 00854530     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001320050225     Document Type: Article

References (30)

1. Raue F, Grauer A (1997) Bisphosphonate bei Knochenstoffwechselerkrankungen, Arzneimitteltherapie 15: 180-187
2. Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF (1996) A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res 11: 150-159
3. Vitte C, Fleisch H, Guenther HL (1996) Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137: 2324-2433
4. Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M, Ludwig H, Leuenberger P, Burckhardt P, Thiebaud D (1996) Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 18: 133-139
5. Grauer A, Klar B, Knaus J, Scharla SH, Ziegler R (1996) Bisphosphonattherapie des Morbus Paget des Knochens mit Pamidronat. Med Klin 91: 14-19
6. Mundy GR, Guise TA (1997) Hypercalcemia of malignancy. Am J Med 103: 134-145
7. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I (1992) Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340: 1049-1052
8. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334: 488-493
9. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD, Heffernan M, Reitsma DJ (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group [see comments]. N Engl J Med 335: 1785-1791
10. Selby PL, Davies M, Marks JS, Mawer EB (1995) Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate. Clin Endocrinol 43 531-536
11. Wimalawansa SJ (1994) Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy. Clin Endocrinol 41: 591-595
12. Ralston H, Gallagher SJ, Patel U, Dryburgh FJ, Fraser W, Cowan RA, Boyle IT (1989) Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia. Lancet 2 1180-1182
13. Blind E, Raue F, Meinel T, Wuster C, Ziegler R (1993) Levels of parathyroid hormone-related protein (PTHrP) in hypercalcemia of malignancy are not lowered by treatment with the bisphosphonate BM 21.0955. Horm Metab Res 25: 40-44
14. Ralston SH, Thiebaud D, Herrmann Z, Steinhauer EU, Thurlimann B, Walls J, Lichintser MR, Rizzoll R, Hagberg H, Huss HJ, Tubiana Hulin M, Body JJ (1997) Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer 75: 295-300
15. Nussbaum SR, Warrell RP, Rude R, Glusman J, Bilezikian JP, Stewart AF, Stepanavage M, Sacco JF, Averbuch SD, Gertz BJ (1993) Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. J Clin Oncol 11: 1618-1623
16. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE (1995) A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 72: 1289-1293
17. Paterson AH (1997) Should bisphosphonates be standard therapy for bone pain? Support Care Cancer 5: 200-204
18. Purohit OP, Anthony C, Radstone CR, Owen J, Coleman RE (1994) High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 70: 554-558
19. Ernst DS, Brasher P, Hagan N, Paterson AH, MacDonald RN, Bruera E (1997) A randomized, controlled trial of intravenous clodronate in patients with metastatic bone pain. J Pain Symptom Manage 13: 319-326
20. Coleman RE, Rubens RD (1987) The clinical course of bone metastases in breast cancer. Br J Cancer 55:61
21. Hortobagyi GN, Theriault RL, Porter L, Blayney O, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD, Heffernan M, Reitsma DJ (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group [see comments]. N Engl J Med 335: 1785-1791
22. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11: 59-65
23. Boissier S, Megnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P (1997) Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized bone extracellular matrices. Cancer Res 57: 3890-3894
24. Takai E, Yano T, Iguchi H, Fukuyama Y, Yokohama H, Asoh H, Ichinose Y (1996) Tumor-induced hypercalcemia and parathyroid related protein in lung carcinoma. Cancer 78: 1384-1387
25. Clemens MR, Fessele K, Heim ME (1993) Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications. Ann Hematol 66: 141-146
26. van der Pluijm G, Vloedgraven H, van Beek E, van der Wee Pals L, Lowik C, Papapoulos S (1996) Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98: 698-705
27. Shipman CM, Rogers MJ, Apperley JF, Russel RGR, Croucher PI (1997) Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumor activity. Br J Haematology 98: 665-672
28. Diel I, pers. Mitteilung
29. van Holten-Verzantvoort ATM, Hermans J, Beex LVAM, Blijham G, Cleton FJ, van Eck-Smit BCF, Sleeboom HP, Papapoulos SE (1996) Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients. Eur J Cancer 32A 450-454
30. Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul S, Bastert G (1992) Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor of distant metastases. J Clin Oncol 10: 1534-1539